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Abstract
Background The off-label use of recombinant activated
factor VII (rFVIIa) for intractable bleeding is associated
with a risk of thrombotic events. The objective of this study
was to evaluate the incidence and predictors of rFVIIa-
related thrombotic events and its efficacy in the reduction
of transfusion requirements during various surgeries.
Methods Ninety-two cases received rFVIIa for uncon-
trollable bleeding despite medical and surgical hemostasis.
The incidence and risk factors of thrombotic events were
analyzed. Blood products transfused in the 24 h before and
after rFVIIa injection were calculated. Subgroup analysis
was performed to see which types of surgeries benefited
most from rFVIIa.
Results The main indication for rFVIIa administration
was uncontrollable bleeding during cardiothoracic surgery
followed by coagulopathy due to liver failure followed by
neurosurgical procedures. Requirements of blood products
after rFVIIa decreased significantly by 45 % (p = 0.012),
52 % (p = 0.0001), and 75 % (p = 0.0001) for red blood
cells, plasma, and cryoprecipitate, respectively. Subgroup
analysis showed that cardiothoracic surgery was the sole
group that benefited from rFVIIa with a reduction in
transfusion of red blood cells (p = 0.013), plasma
(p = 0.0001), and cryoprecipitate (p = 0.0001). Throm-
botic events occurred in 9.8 % of the cases mostly on the
arterial side (89 %) and have not contributed to mortality.
Conclusion rFVIIa can significantly reduce transfusion
requirements when given for intractable bleeding during
cardiothoracic surgery at the expense of thrombotic events
in approximately one tenth of the cases. Further prospec-
tive studies are necessary to study if this effect of rFVIIa is
translated to a favorable outcome.
1 Introduction
Recombinant activated factor VII (rFVIIa; NovoSeven,
Novo Nordisk, Copenhagen, Denmark) is a genetically
engineered concentrate of the activated form of human
coagulation factor VII. The original design and on-label
indication of rFVIIa is the treatment of life-threatening
hemorrhages in patients with hemophilia A and B and
acquired hemophilia [1]. In this group of patients, the
prevalence of rFVIIa-related thromboembolic events is less
than 1 % and its safety has been well studied in prospective
clinical trials. Given the rarity of these diseases, more than
95 % of rFVIIa administration is for off-label indications
[2]. Recently, rFVIIa has been increasingly used in a va-
riety of off-label indications including cardiac surgery [3,
4], liver transplantation [5], trauma [6], and extracorporeal
membrane oxygenation [7]. Although the use of rFVIIa in
uncontrollable bleeding is not associated with mortality
benefit [8, 9], several studies have shown an improved
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outcome [10, 11]. Nonetheless, concerns have been raised
regarding the increased risk of thrombotic events [12–14],
the main argument for limiting rFVIIa off-label use.
A Cochrane review of 29 randomized controlled studies
including 4290 patients showed weakness of evidence
supporting rFVIIa off-label use and suggested that its use
should be restricted to clinical trials [9]. Given the lack
of sufficient evidence supporting rFVIIa off-label use, a
careful risk/benefit assessment is therefore crucial in
deciding when to administer rFVIIa to those with un-
controllable bleeding. To examine the safety and efficacy
of the off-label use of rFVIIa at our facility we have
conducted this observation study. We aim to assess the
incidence and independent predictors for the occurrence
of thrombotic events and the efficacy of rVIIa in con-
trolling massive bleeding in various surgical and medical
settings.
2 Materials and Methods
2.1 Study Design and Study Population
A retrospective review of medical records was performed
for consecutive patients who received rFVIIa for
uncontrollable bleeding between October 2011 and
December 2013 at a 1018-bed tertiary care facility;
Tampa General Hospital. The patients who received
rFVIIa were identified from pharmacy records and were
included in the study if they were aged 18 years or older
and received at least one dose of rFVIIa. Uncontrollable
bleeding is defined as persistent bleeding despite the
implementation of medical and surgical hemostatic
measures. Thrombotic events were determined through
review of progress notes and discharge summary of cases
receiving rFVIIa. Diagnosis of thrombotic events was
made by ultrasonography for peripheral venous or arterial
thrombosis and computed tomography scan for ischemic
cerebrovascular stroke or pulmonary artery embolism.
The Institutional Review Board at the University of
South Florida approved the study and waived the need
for patient consent.
2.2 Administration of rFVIIa
Commercially available rFVIIa was used in all patients
included in the study. The decision to inject the drug was at
the onset of uncontrollable bleeding despite transfusion of
blood products. The dosage and number of injections of
rFVIIA was decided based upon a Tampa General Hospital
protocol for non-US Food and Drug Administration-ap-
proved uses of rFVIIa (supplementary Appendix).
2.3 Study Endpoints
The main outcome variable of this study was to determine
the incidence and predictors of occurrence of thrombotic
events related to rFVIIa administration. We reviewed
medical records for baseline risk factors that may increase
the risk for thromboembolism. Approximately 20 risk
factors were investigated including age, sex, body mass
index, diabetes mellitus, prior history of thrombotic events,
history of cancer, rFVIIa dose, number of rFVIIa doses
given, and concomitant administration of blood products to
determine independent predictors of rFVIIa-related
thromboembolic events. The secondary outcome variable
was to assess the efficacy of rFVIIa in reducing transfusion
requirements in various surgical and medical indications.
Various blood products administered, including packed red
blood cells (RBCs), platelets, plasma, and cryoprecipitate,
were collected in the 24 h before and after injecting rFVIIa
to observe its effect on reducing transfusion requirements.
Subgroup analysis was performed to identify which sub-
group benefited most from rFVIIa administration.
2.4 Statistical Analysis
The Kolmogorov–Smirnov test was used to assess the nor-
mality of distribution of investigated parameters. Continuous
data were expressed as means ± standard deviations and
were compared using two-tailed independent Student t tests.
Categorical variables were compared using Chi-Square or
Fisher’s exact tests. Subgroup analysis to see the group who
benefited most from rFVIIa administration was performed
using the paired t test.Multivariate logistic regression analysis
was used to identify independent predictors for the occurrence
of thrombotic events after rFVIIa administration. p\ 0.05
was considered significant. Data were analyzed using IBM
SPSS 21.0 statistical software (Version 21.0., IBM SPSS
Statistics for Windows, Armonk, NY, USA).
3 Results
A total of 92 consecutive patients who received rFVIIa
were enrolled in the study. rFVIIa was given to control
bleeding during surgery in 70 patients (76.1 %) and for
various medical indications causing intractable bleeding in
22 patients (23.9 %). rFVIIa was administered in an av-
erage dose of 62 lg/kg. Twelve cases received two doses
and three cases received three doses of rFVIIa. Figure 1
illustrates the various indications for rFVIIa administration.
The main indications for administration of rFVIIa were
uncontrollable bleeding during cardiothoracic surgery
(46 % of cases) followed by reversal of bleeding due to
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liver failure (19.1 %), followed by neurosurgical proce-
dures (16 %). Figure 2 lists the various prescribing services
of each rFVIIa injection showing that anesthesiologists
were the most frequent prescribers of rFVIIa. Demo-
graphics and clinical characteristics for patients with and
without thrombotic events are summarized in Table 1.
There were no significant differences in baseline demo-
graphics, clinical characteristics, preoperative coagulation
tests, rFVIIa dose and number of injections, and transfusion
of various blood products between both groups.
3.1 Transfusion Requirements Before and After
rFVIIa Administration
For the 92 patients included in the study, bleeding sig-
nificantly decreased after the administration of rFVIIa as
evidenced by the diminished need for blood products
(Table 2). Requirements of blood products after rFVIIa
decreased significantly by 45 % (p = 0.012), 52 %
(p = 0.0001), and 75 % (p = 0.0001) for RBCs, plasma,
and cryoprecipitate, respectively. There was a non-sig-
nificant reduction in platelet transfusions after rFVIIa by
30 %, p = 0.142. Subgroup analysis according to the
indication for rFVIIa administration showed that cardio-
thoracic surgeries had the most benefit after rFVIIa injec-
tion in terms of a reduction in transfusion requirements. In
patients undergoing cardiothoracic surgery, there was a
significant reduction in RBCs (p = 0.013), plasma
(p = 0.0001), and cryoprecipitate (p = 0.0001) after
rFVIIa administration (Fig. 3). With neurosurgical proce-
dures, there was only a trend towards a decreased need for
platelet transfusion after rFVIIa administration (p = 0.057)
but no significant effect on RBC, plasma, or cryoprecipitate
transfusion (Fig. 4). With other procedures, which include
trauma, gastrointestinal bleeding, postoperative bleeding,
and liver transplant, the use of rFVIIa has not significantly
decreased the transfusion of any blood products (Fig. 5).
3.2 rFVIIa-related Thrombotic Events
and Predictors of Thrombosis
Thrombotic events were identified in 9/92 patients (9.8 %).
Out of the nine thrombotic events, four occurred after
cardiac surgery, two after neurosurgery, and three follow-
ing liver transplant. The majority of thrombotic events
occurred in the arterial circulation: two cases in the pul-
monary artery, three cases in the cerebral circulation
causing cerebrovascular infarcts, and one case in the
common femoral vein, radial artery, hepatic artery, and
brachiocephalic artery. We found no difference between
subjects with and without thrombotic events with regard to
various risk factors of thrombosis on univariate analysis
(Table 1). At the multivariate logistic regression model
(Nagelkerke R2: 0.113; p from the Hosmer–Lameshow
test = 0.709), we found no independent predictors of oc-
currence of thrombotic events in patients receiving rFVIIa
(Table 1). Mortality data were available for all patients.
The mortality rate in the groups that received rFVIIa with
and without thrombotic events was 66.7 % and 57.8 %,
respectively, p = 0.609. Mortality was unrelated to the
occurrence of thrombotic events.
4 Discussion
In prior studies, rFVIIa did not show evidence of reducing
mortality from uncontrollable bleeding while thrombotic
events remained a major concern. This has stimulated rec-
ommendations curtailing its off-label use [15]. However, an
Fig. 1 The various indications for the administration of rFVIIa at
Tampa General Hospital between October 2011 and December 2013.
rFVIIa recombinant activated factor VII, SAH subarachinoid hemor-
rhage, SDH subdural hemorrhage
Fig. 2 The various prescribing services of each rFVIIa injection at
Tampa General Hospital between October 2011 and December 2013.
ACCM anesthesia critical care medicine, CC critical care, CT
computed tomography, ED emergency department, MICU medical
intensive care unit, rFVIIa recombinant activated factor VII
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improved outcome was found with the off-label use of
rFVIIa in cases with uncontrollable coagulopathic bleeding
unresponsive to conventional therapy [16–21] and this has
been supported by two major studies. In a recent multicenter
study at 16 Canadian hospitals for which 1378 cases re-
ceived rFVIIa, transfusion requirements were substantially
decreased after the administration of rFVIIa and the rate of
adverse events was strongly related to the severity of
bleeding [10]. The severity of bleeding undermined any
potential risks related to thrombotic events and authors felt
that major bleeding was the main determinant of outcome.
Additionally, the Australian and New Zealand Registry
found a strong relationship between lack of response to
rFVIIa and mortality [22]. This promoted many to favor the
use of rFVIIa when the risk/benefit ratio is favorable, as in
life-threatening coagulopathy after surgery or trauma.
Table 1 Characteristics of patients who received rFVIIa with or without the occurrence of thrombotic events at the Tampa General Hospital
between October 2011 and December 2013
Characteristic Thrombotic event (n = 9) No thrombotic event (n = 83) p value* p value**
Age (y) 53.7 ± 18.6 58.6 ± 16.6 0.403 0.246
Weight (kg) 87.4 ± 23.5 86 ± 23.3 0.867
Height (m) 1.7 ± 0.1 1.7 ± 0.1 0.659
BMI (kg/m2) 28.2 ± 5.2 28.4 ± 7.4 0.961 0.725
Preop PLT (109/L) 87 ± 33.9 124.5 ± 81 0.526
Preop PT (s) 20.5 ± 10.4 20.2 ± 15.9 0.945
Preop PTT (s) 45.7 ± 18 38.9 ± 24.8 0.433
Preop INR 2 ± 1 1.9 ± 1.5 0.934
rFVIIa dose (mcg) 5666 ± 3807 5409 ± 3721 0.845 0.824
Sex (% female) 44.4 37.3 0.677
History of cancer (%) 0 18.1 0.186 0.999
DM (%) 11.1 36.1 0.125
CAD (%) 44.4 42.2 0.582
Coagulopathy (%) 44.4 28.9 0.273
History of thrombosis (%) 22.2 13.3 0.373
Number of rFVIIa doses 1.1 ± 0.3 1.2 ± 0.5 0.576 0.611
1 dose rFVIIa (%) 88.9 83.1 0.824
2 doses rFVIIa (%) 11.1 13.3 0.824
3 doses rFVIIa (%) 0 3.6 0.824
Concomitant FFP (%) 37.5 50 0.402
Concomitant amicar (%) 62.5 44.7 0.3
Concomitant PLT (%) 37.5 36.8 0.634
Mortality, n (%) 6/9 (66.7) 48 (57.8) 0.446
BMI body mass index, CAD coronary artery disease, DM diabetes mellitus, FFP fresh frozen plasma, INR International Normalized Ratio, Preop
preoperative, PLT platelet, PT prothrombin time, PTT partial thromboplastin time, rFVIIa recombinant activated factor VII
* p value for univariate analysis
** p value for multivariate analysis
Table 2 Transfusion of blood products before and after the administration of rFVIIa at the Tampa General Hospital between October 2011 and
December 2013
Blood product 24 h before rFVIIa
(mean ± SD)




95 % CI p value
RBC 11.8 ± 17.3 6.5 ± 14.8 5.3 1.2 to 9.4 0.012*
Platelet 18 ± 26.4 12.6 ± 26.1 5.5 -1.9 to 12.8 0.142
Plasma 9.7 ± 9.9 4.7 ± 7 5 2.6 to 7.5 0.0001*
Cryoprecipitate 22.6 ± 33 5.7 ± 17.1 16.9 9.4 to 24.4 0.0001*
a The absolute difference in blood products in the 24 h before and 24 h after rFVIIa administration
CI confidence interval, RBC red blood cells, rFVIIa recombinant activated factor VII, SD standard deviation
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In our study, the administration of rFVIIa reduced
bleeding as evidenced by the significant reduction in
transfusion requirements of RBCs, plasma, and cryopre-
cipitate in the 24 h after its injection compared with the
blood products required in the prior 24 h. For accuracy, the
amount of transfusion products rather than estimated blood
loss was used as a marker of severity of bleeding. rFVIIa
was used mainly in uncontrollable bleeding after cardio-
thoracic surgery followed by reversal of coagulopathy due
to liver cell failure followed by neurosurgical procedures.
Analysis of transfusion requirements in various subgroups
show that those undergoing cardiothoracic surgery
Before rFVIIa
Aer rFVIIa
RBC Platelet Plasma Cryo
20.3 25.3 14 48.9














P= .013* P= .6 P= .0001* P= .0001*
Fig. 3 Effect of rFVIIa on the
transfusion of blood products
during cardiothoracic surgery.
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transfusion of blood products
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Fig. 5 Effect of rFVIIa on the
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for other surgical and medical
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benefited the most from rFVIIa administration in terms of a
reduction in transfusion requirements, as they demon-
strated a significant reduction in RBCs, plasma, and
cryoprecipitate transfusion after rFVIIa injection. The re-
duction in transfusion requirements has not been significant
in the neurosurgical group and other procedures, suggest-
ing a favorable benefit of rFVIIa in cardiothoracic surgery.
Possible explanation for this difference in efficacy is the
vascular nature of cardiac surgery in addition to the likely
significantly higher use of antiplatelet medications and
possible continued effect of anticoagulant medications in
this group compared with liver cell failure and neurosur-
gical groups.
Our study confirms the results of prior studies including
a randomized placebo-controlled trial that showed a sig-
nificant reduction in the number of patients requiring re-
operation after cardiac surgery as a result of bleeding
(p = 0.03), as well as a reduction in allogenic transfusions
(p = 0.01) [23]. Another randomized controlled study
comparing the efficacy of the prophylactic use of rFVIIa
given after weaning from cardiopulmonary bypass (CPB)
showed a significant reduction in postoperative bleeding
and transfusion requirements [24]. Anderson and col-
leagues reported the value of low-dose rFVIIa given after
CPB in improving postoperative hemostasis in a propen-
sity-matched cohort of 88 patients undergoing thoracic
aortic operations [25]. In a multicenter observational study,
Hacquard and colleagues demonstrated the value of rFVIIa
in reducing hourly blood loss (p\ 0.001) and transfusion
requirements (p\ 0.001) in patients with intractable
hemorrhage after cardiothoracic surgery [26]. This reduc-
tion in blood loss and transfusion requirements with rFVIIa
was also demonstrated in children undergoing cardiac
surgery with CPB [27].
However, these results should be taken with caution
after a study by Alfirevic and colleagues of 144 propensity-
matched patients who received rFVIIa before complex
cardiac surgery showed a higher in-hospital mortality (40
vs 18 % of control patients, odds ratio 2.82; 98.3 % con-
fidence interval 1.64–4.87; p\ 0.001) and renal morbidity
(31 vs 17 % of control patients (odds ratio 2.07; 98.3 %
confidence interval 1.19–3.62; p = 0.002) after adjustment
for major confounding variables [28]. Additionally, in an
earlier study by Chapman and colleagues who matched 236
patient receiving rFVIIa for bleeding after cardiac surgery,
although there was no significant difference in mortality
between both groups, there was a higher trend in 30-day
mortality (7.7 vs 4.3 % in the rFVIIa group and control
group, respectively, p = 0.14) 29]. However, in these
studies the possibility of influence of unmeasured con-
founders cannot be totally excluded.
We found a 9.8 % incidence of thrombotic events con-
forming to prior studies showing similar incidence [30].
None of these events have contributed directly to mortality.
We examined all possible predictors for occurrence of
thrombotic events but none showed significance. This can
also be a function of small sample size. Eighty-nine percent
(eight of nine cases) of thrombotic events occurred on the
arterial side with only one case of venous thrombosis in the
common femoral vein. This confirms the results of a prior
meta-analysis that included 35 randomized clinical trials
and showed a significantly higher rate of arterial throm-
boembolic events among those who received rFVIIa than
among subjects who received placebo, but a comparable
rate of venous thromboembolic events among both groups
[12].
The main study limitation is the small cohort and the
retrospective design. We have not used blood loss data
because of concerns of accuracy of provided values and
instead used transfusion requirements as a marker of
severity of bleeding. The benefit of rFVIIa in reducing
transfusion requirements should not be generalized to the
whole study population, as it is mainly driven by a highly
significant reduction in the transfusion of blood products in
the cardiothoracic surgery group and this benefit was re-
sponsible for continued statistical significance when the
whole group was analyzed. Another limitation is the un-
clear description of intractable bleeding in our study.
rFVIIa was given at the discretion of the various pre-
scribers as outlined in Fig. 2 without clear-cut definitions
and therefore some of these injections might be unneces-
sary and cause more harm than benefit. The dosage and
number of rFVIIa injections were also not standardized
across the study subjects, which is an inherent limitation in
most retrospective studies. Subgroup analysis is inherently
challenging as one must account for the heterogeneity in
baseline characteristics in different subgroups, loss of
power with repeated analysis, and the risk of type 1 error.
However, the fact that the p value for the reduction in
plasma and cryopercipetate transfusion after rFVIIa ad-
ministration in cardiothoracic surgery is 0.0001 suggests
that these results will likely be reproducible. Because our
main study objective was to find predictors for the occur-
rence of thrombotic events after rFVIIa injection, a control
group of patients (who had not received rFVIIa) was not
included in the study, and therefore mortality and mor-
bidity after rFVIIa injection was not analyzed and can be
related to other non-thrombotic side effects.
5 Conclusion
This observational study demonstrates a significant reduc-
tion in transfusion requirements in the patients undergoing
cardiothoracic surgery with thrombotic events occurring in
approximately one tenth of the cases with no clear
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predictors for the occurrence of these events. In this study,
thrombotic events had not contributed directly to mortality.
rFVIIa may therefore be of benefit in reducing transfusion
requirements from intractable bleeding during cardiotho-
racic surgery. Further randomized prospective studies are
necessary to study the morbidity and mortality outcomes of
rFVIIa compared with placebo.
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